UserTesting’s Eighth Annual CX Survey Reveals That Customer Empathy Is No Longer Optional
24.3.2021 16:00:00 EET | Business Wire | Press release
UserTesting, a leading provider of on-demand human insights, today released new data identifying how the pandemic has put customer experience (CX) and empathy center stage. Findings show that businesses are in one of two categories, those doubling down on CX and those scaling back on it, and that customer feedback collection is on the rise, with 72 percent of organizations stating that they plan to increase their investments in 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005313/en/
UserTesting 2021 CX Industry Report (Graphic: Business Wire)
The vast majority, 71 percent, noted that they’re either in-process or have completed their digital transformation. This is a sharp increase from 2019 survey results, in which only 56 percent said they were that far along in their journey. This indicates that the pandemic has helped to motivate teams to dedicate more time and resources to digital transformation to improve overall CX.
The 2021 CX Industry Report uncovered three key trends influencing customer experience today:
-
Feedback has gone remote
The remote-centric business environment brought about by the pandemic is, for many, here to stay. A remote-first approach to customer feedback is a new strategy that many companies will continue to embrace into the new normal, and for good reason. The survey revealed that moving to online user research can cut costs by an average of 40 percent. The impact on a company’s bottom line is also significant. Moving to online user research was found to increase revenue by about 40 percent. Many survey respondents noted that the pandemic will permanently reduce the amount of in-person research they do moving forward.
-
The pandemic has put the focus on CX
Although consumers’ interactions with brands have changed, expectations have never been higher. The survey found that companies acknowledge an increase in the use of customer feedback, which drove more investments into customer feedback and user research. Both trends are likely to continue. Despite the efforts to improve CX, many survey respondents noted their companies are still in the early stages of establishing their CX practices with 60 percent admitting that their organization doesn’t have a formal CX strategy in place or only reacts to issues as they happen.
-
Teams are doing more with less
Time and resources were significantly impacted by the pandemic which, in many cases, meant more work with fewer resources. Nearly 70 percent of those surveyed reported reductions in spending or workforce resources due to business changes caused by the pandemic. Fewer resources impacted nearly half of those surveyed with 53 percent reporting an increase in workload. The pandemic also required many companies to quickly pivot their product or service offerings. Forty-six percent of respondents reported a change to their product roadmap due to the pandemic.
“We have been through a year unlike any other where organizations have had to adapt to changing customer needs. The past year has shown that organizations must prioritize customer understanding and empathy to build long term customer loyalty,” said Janelle Estes, Chief Insights Officer at UserTesting. “The takeaway for every size organization should be that talking with and listening to your customers cannot take place only during times of crisis but should be part of regular business practices.”
To access the full UserTesting 2021 CX Industry Report, click here.
Methodology and survey results
In this eighth annual Customer Experience Industry Survey, we asked over 4,700 professionals from around the world across a wide variety of industries how their organizations are approaching customer experience and conducting CX research.
About UserTesting
UserTesting enables every organization to deliver the best customer experience powered by human insight. With UserTesting’s on-demand Human Insight Platform, companies across industries make accurate customer-first decisions at every level, at the speed business demands. With UserTesting, product teams, marketers, digital, and customer experience executives, designers and UX researchers confidently and quickly create the right experiences for all target audiences, increasing brand loyalty and revenue. UserTesting customers include more than half of the world’s top brands. UserTesting is headquartered in San Francisco, CA. To learn more, visit www.usertesting.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005313/en/
Contact information
UserTesting, Inc.
Chris Halcon
415-699-0553
chalcon@usertesting.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 16:00:00 EEST | Press release
Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is strengthening its position through the acquisition of a VCSEL company for short-range communications five years ago and the completion of 100G (25G×4) class technology. Furthermore, Seoul Viosys is ex
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 15:51:00 EEST | Press release
vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports enamel repair by facilitating the formation of crystalline mineral structure throughout the affected area, giving dental professionals an easy-to-use, restorative opti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
